Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Perspectives

Commentary on androgen deficiency in women and the FDA advisory board's recent decision to request more safety data

Abstract

Editor's note:The FDA's decision regarding Intrinsa has potential widespread implications for the medical treatment of female sexual dysfunction (FSD). Dr Andre Guay is a world-renowned authority on the topic of female sexuality and FSD. Accompanying Dr Spark's perspective in issue 2, this perspective will shed important light on the topic and offer insight into the past, present and future of FSD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Guay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guay, A. Commentary on androgen deficiency in women and the FDA advisory board's recent decision to request more safety data. Int J Impot Res 17, 375–376 (2005). https://doi.org/10.1038/sj.ijir.3901332

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901332

Search

Quick links